The six-month international IDEAL (Investigation of transDermal Exelon in ALzheimer’s disease) trial, involving 1,195 patients with Alzheimer’s disease, showed that the demonstrated significant improvements across a range of symptoms including memory and ability to perform everyday activities, compared with placebo.
The 9.5mg/24hr patch provided similar efficacy to the highest doses of rivastigmine capsules (12mg/day) with a superior tolerability profile. Over 70 per cent of caregivers preferred the patch formulation to oral medication with respect to overall ease of use.
The patches are available in two strengths: 4.6mg/24hr and 9.5mg/24hr. The initial dose is one 4.6mg/24hr patch. After a minimum of four weeks and if well tolerated, this should be increased to the recommended effective dose of 9.5mg/24hr.
Further information: Novartis 01276 692255